Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries.
about
The changing landscape of biosimilars in rheumatologyComparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysisDeterminants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data.Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.HTA Implementation Roadmap in Central and Eastern European Countries.Use of biologics for psoriasis in Central and Eastern European countries.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe.Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: A systematic review and meta-analysis.Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis.Access to biologicals in Crohn's disease in ten European countriesMapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis.Jatrorrhizine Hydrochloride Suppresses Proliferation, Migration, and Secretion of Synoviocytes In Vitro and Ameliorates Rat Models of Rheumatoid Arthritis In Vivo.
P2860
Q26766515-326FD1A5-B6D1-446A-B31A-A3571E3B9918Q26828622-75B22815-B940-4224-BD16-68353758B5BFQ31167447-A07DA4CA-6A7F-43D9-A226-133CDA1395CBQ33713261-A275B9B5-F206-417B-9BA8-7721B8CCE349Q35069447-9FC95C6A-1052-444C-9147-553DC4FBD1F4Q37343970-C9318874-DB99-4AFE-B07B-9D60DC52BFB3Q38586836-818673A5-A7B3-4D85-9925-4501288D81FBQ38708927-61BF7384-E386-40A3-B033-77F05C21B352Q38785383-EBE5D120-6E17-416A-B5AC-9B5853DDC488Q38893192-68B4F0DD-85A6-4DAD-BD31-155F87A2E2FBQ39357716-9498A5BF-18B7-4C53-9376-730D74CCFE24Q39690382-77722D99-845E-4445-B2EF-6C78D90B509EQ42044847-86D8ADBF-7D49-4911-BFB0-1E6F024FA05DQ47375172-4908FF99-7408-479C-A2DB-2234575AB2FBQ54968721-C715BC3C-17FC-4344-A760-291CF428465A
P2860
Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biological therapy in inflamma ...... nd Eastern European countries.
@en
type
label
Biological therapy in inflamma ...... nd Eastern European countries.
@en
prefLabel
Biological therapy in inflamma ...... nd Eastern European countries.
@en
P2093
P2860
P1476
Biological therapy in inflamma ...... nd Eastern European countries.
@en
P2093
Catalin Codreanu
Gyula Poór
László Gulácsi
Marek Brzosko
Márta Péntek
Nóra Brodszky
Piotr Wiland
P2860
P2888
P304
P356
10.1007/S10198-014-0592-6
P478
15 Suppl 1
P50
P577
2014-05-16T00:00:00Z